Gene Mutation Profile in Chronic Myelogenous Leukemia BCR-ABL. Positive Chronic Phase Patients Which not Response to lmatinib Treatment in Dr. Soetomo Teaching Hospital Surabaya lndonesia
| Main Author: | Ugroseno Yudho Bintoro, Siprianus |
|---|---|
| Format: | Article PeerReviewed Book |
| Bahasa: | eng |
| Terbitan: |
The Korean Association of Internal Medicine
, 2014
|
| Subjects: | |
| Online Access: |
http://repository.unair.ac.id/53490/1/karil13.%20Gene%20Mutation%20Profile.pdf http://repository.unair.ac.id/53490/2/peerreview13.Gene%20Mutation%20Profi23022017091215.pdf http://repository.unair.ac.id/53490/ http://www.kjim.org |
Daftar Isi:
- To determine patterns of gene mutations in BCR-ABL tyrosine kinase in chronic myelogenous leukemia BCR-ABL positive chronic phase are not complete molecular response to lmatinib treatment methods: Gene Mutation Analysis has been done in sixteen chronic myelogenous leuki mia patients with BCR-ABL positive chronic phase who are not complete molecular response to lmatinib after 18 months treatment Result: We found C944T gene mutation in 9 (56,25%) patients, T1O52C gen mutation in 16 patient (100%), and T932C gene mutation in 13 patients (81,25%). One Type of Mutation found in one patient, two types of mutations in six patients, and three type mutations in nine patients Conclusion : No siqnificant effect of the C944T mutation and the T932C mutation with a single mutation of the tyrosine kinase drug resistance. Ihere is influence of the T1052C single mutation to tyrosine kinase drug resistance.